Aurora kinase A in gastrointestinal cancers: time to target

Ahmed Katsha, Abbes Belkhiri, Laura Goff and Wael El-Rifai

Abstract

Gastrointestinal (GI) cancers are a major cause of cancer-related deaths. During the last two decades, several studies have shown amplification and overexpression of Aurora kinase A (AURKA) in several GI malignancies. These studies demonstrated that AURKA not only plays a role in regulating cell cycle and mitosis, but also regulates a number of key oncogenic signaling pathways. Although AURKA inhibitors have moved to phase III clinical trials in lymphomas, there has been slower progress in GI cancers and solid tumors. Ongoing clinical trials testing AURKA inhibitors as a single agent or in combination with conventional chemotherapies are expected to provide important clinical information for targeting AURKA in GI cancers. It is, therefore, imperative to consider investigations of molecular determinants of response and resistance to this class of inhibitors. This will improve evaluation of the efficacy of these drugs and establish biomarker based strategies for enrollment into clinical trials, which hold the future direction for personalized cancer therapy. In this review, we will discuss the available data on AURKA in GI cancers. We will also summarize the major AURKA inhibitors that have been developed and tested in pre-clinical and clinical settings.

Keywords: Aurora kinases, Therapy, AURKA inhibitors, MNL8237, Alisertib, Gastrointestinal, Cancer, Signaling pathways

Introduction

Mitotic kinases are the main proteins that coordinate accurate mitotic processing [1]. In lower organisms, mitotic kinases include polo-like kinases, NIMA-related kinases, cyclin-dependent kinase 1, WARTS/LATS1-related kinases, and Aurora/Ipl1-related kinases [2]. In humans, the aurora kinase family is considered homologous to Aurora/Ipl1 kinases [2]. This family consists of highly conserved serine-threonine kinases, which play a critical role in regulation of mitotic events like spindle assembly, function of centrosomes and cytoskeleton, and cytokinesis [3,4]. Members of this family are Aurora kinase A (AURKA), Aurora kinase B (AURKB), and Aurora kinase C (AURKC) [3,4]. AURKA is located at chromosome 20q13.2 [5,6] and was found to play an important role during mitosis. It has been shown that AURKA knockdown suppresses centrosome maturation [7,8]. In mice, AURKA genetic ablation or null mutation leads to mitotic arrest and embryonic death at the blastocyst stage [9-11]. Furthermore, AURKA is critical for bipolar-spindle assembly where it interacts with Ran-TPX2 pathway [12]. In addition to its role in mitosis, AURKA is recently reported to regulate stem cell self-renewal, reprogramming, and differentiation [13,14]. Overexpression of AURKA has been reported to impair DNA damage repair through inhibition recruitment of RAD51 to double strands breaks [15]. Additionally, AURKA was found to suppress BRCA1 and BRCA2, both play a major role in DNA damage response [16,17]. Furthermore, AURKA was also reported to regulate cell migration and adhesion [18] and to mediate an increase in VEGF mRNA expression [19]. AURKA activity is dependent on its phosphorylation at the 288-threonine residue (T288); located on the activation loop of the kinase. AURKA is activated through an autophosphorylation process upon binding with TPX2 [12,20], along with several other kinases. AURKA signaling networks are summarized in Table 1 and Figure 1.

Several studies have shown that AURKA is frequently amplified in several tumors including breast, leukemia,
bladder, ovarian, gastric, esophageal, liver, colorectal, and pancreatic cancers [21-30]. Notably, AURKA overexpression has been significantly associated with high-grade (grade II-IV) and high-stage (stage IIIB-IV) hepatocellular carcinoma tumors [30]. Furthermore, it was suggested that AURKA is an essential mediator of chemoresistance in colorectal and breast cancers [31,32]. Importantly, several studies indicated that AURKA overexpression directly leads to malignant transformation and tumor formation [25,33,34]. Additionally, AURKA inhibition or knockdown was shown to induce senescence in multiple myeloma [35] and colon cancer cells [36]. Together, these findings strongly suggest the key role of AURKA in tumorigenesis, and thus, underscore AURKA as an attractive target for cancer therapy.

### Table 1 Selected cancer associated proteins regulated by AURKA

| Protein | Type of regulation | Functional significance | References |
|---------|--------------------|-------------------------|------------|
| p53     | Phospho-Ser215     | Abrogates transactivation | [48,56]    |
|         | Phospho-Ser315     | Abrogates transactivation and enhances proteasomal degradation |          |
| NF-κBp65| Phospho-Ser536     | Promotes inflammation and cell survival | [49]       |
| P73     | Phospho-Ser235     | Induces apoptosis        | [52-56]    |
| MDM2    | Phospho-Ser166     | Activates MDM2 and degradation of p53 | [48]       |
| GSK3β   | Phospho-Ser9       | Inhibits GSK3β and enhances β-catenin activity | [19]       |
| IkBα    | Phospho-Ser32      | Induces degradation of IkBα and activation of NF-κB pathway | [49]       |
| JAK2    | Increased expression| Activates STAT3          | [55]       |
| N-MYC   | Increased expression| Stabilizes N-MYC protein  | [106]      |
| SRC     | Phospho-Tyr416     | Activates SRC and promotes cancer cell invasion | [18]       |
| IκKα/β  | Phospho-Ser176/180 | Activates NF-κB pathway  | [107]      |
| NF-κBp2/p100 | Phospho-Ser866/870   | Activates non-canonical NF-κB pathway | [108]     |
| STAT3   | Phospho-Tyr705     | Promotes cell survival   | [55]       |
| RalA    | Phospho-Ser194     | Enhances transformed cell growth | [74]       |
| BRCA1/BRCA2 | Decreased expression | Down-regulate cell cycle and DNA damage response | [16,17,109] |

**AURKA in gastrointestinal cancers**

Cancers can develop in any anatomical site of the GI system including esophasus, stomach, small intestine, colon, rectum, liver, gall bladder, and pancreas. A cancer in any of these organs represents a unique type where different molecular mechanisms of tumorigenesis can exist. Recent studies have shown that AURKA is frequently overexpressed and/or amplified in several GI cancers [25-28]. In the following sections, we will review and discuss some of the recently reported studies about AURKA functions in GI cancers.

**AURKA in upper gastrointestinal cancers**

Upper gastrointestinal (UGI) cancers include tumors of the stomach and esophagus. While esophageal squamous cell carcinoma (ESCC) is the predominant histological type of esophageal cancers in the world, there has been a significant increase in the incidence of gastroesophageal reflux-related esophageal adenocarcinomas (EAC) in the Western world [41]. The majority of gastric cancers are adenocarcinomas; other subtypes such as lymphomas and gastrointestinal stromal tumors are rare and will not be discussed in this review. Amplifications of chromosomal region 20q13, where AURKA is located, have been described in gastric and esophageal cancers [42,43]. Polymorphisms in the AURKA gene have also been reported in UGI cancers [44,45]. Several studies have shown frequent overexpression of AURKA at the mRNA and protein levels in ESCC, EAC, and gastric cancers [28,46-49].
It has also been suggested that the increased AURKA expression might be used as a prognostic marker of ESCC [50]. In addition, overexpression of AURKA in premalignant and malignant histological stages of reflux-induced Barrett’s tumorigenesis has been reported [51]. Similarly, overexpression of AURKA has been observed in early pre-neoplastic stages of gastric cancer in mouse models and human [49]. Taken together, these reports strongly suggest a critical role for AURKA in carcinogenesis.

Molecular studies have shown that AURKA promotes cell survival signaling while it suppresses the pro-apoptotic machinery in UGI cancer cells [52,53]. We and others have reported that AURKA promotes activation of the AKT pro-survival signaling pathway [47,54]. Furthermore, it has been shown that AURKA can regulate and suppress GSK3β kinase activity in gastric cancer cell lines [19]. The AURKA-GSK3β interaction activates β-catenin/TCF transcription complex, which leads to increased mRNA expression of several oncogenic proteins such as CCND1, c-MYC, c-MYC-binding protein, CLDN1, FGF18, and VEGF [19]. Pro-inflammatory signaling is a significant component in the etiology of tumor development and progression of UGI cancers. In this context, recent reports indicated that AURKA overexpression promotes activation of NF-κB [49] and STAT3 [55] pathways in these cancers. In these studies, AURKA inhibition abrogates the pro-survival and pro-inflammatory signaling mediated by NF-κB and STAT3.
with suppression of key pro-survival target genes such as BCL-xL, BCL2, and MCL1 [49,55]. Some of the main features of cancer cells include resistance to pro-apoptotic stimuli and the ability to overcome genotoxic stress and chemotherapeutic-induced death. We and others have shown that AURKA can suppress p53 pro-apoptotic functions [48,56]. A recent study has shown that AURKA regulates the key ubiquitin ligase involved in degradation of p53, HDM2, whereby overexpression of AURKA enhanced HDM2 stabilization and promoted degradation of p53, thereby abrogating p53 pro-apoptotic function in response to chemotherapy [48]. Not only does AURKA circumvent p53 pathway, but it also provides a mechanism for cancer cells to evade apoptosis by suppressing p73, an important p53 family protein [52,56]. Collectively, these signaling mechanisms mediated by AURKA can promote cancer cell survival and provide a chemoresistance phenotype. These findings also suggest AURKA as part of a signaling hub controlling several key pathways that regulate the hallmarks of the cancer cell network.

Several AURKA inhibitors have been developed to overcome AURKA-mediated pro-survival and anti-apoptotic activities in cancer cells. Inhibition of AURKA using investigational MLN8054 or MLN8237 led to reversal of anti-apoptotic signaling cascades with activation of pro-apoptotic p73 in p53 deficient cells with re-expression of several pro-apoptotic proteins such as PUMA, NOXA, and p21 [52]. AURKA inhibition by small molecule MLN8237 as a single agent or in combination with Cisplatin or Docetaxel significantly enhanced cell death in esophageal adenocarcinoma xenograft mouse model [53,57]. These findings strongly indicate that AURKA could be an important therapeutic target in upper GI cancers.

AURKA in colorectal cancer
Colorectal cancer (CRC) was one of the first cancers found to have AURKA amplification. A 1998 study showed that overexpression of AURKA resulted in centrosome amplification, chromosomal instability and transformation in mammalian cells, including colon cancer cells [34]. Genetic variations in the AURKA gene were also detected and associated with aneuploidy in human colon tumors and low penetrance CRC susceptibility factor [58,59]. AURKA overexpression was associated with the down-regulation of checkpoint with forhead and ring finger domains (CHFR) in colorectal cancers with high microsatellite instability [60]. Importantly, recent reports indicated that AURKA is critical for tumorigenicity and chemoresistance in CRC stem cells [31], and suggested AURKA as a predictive marker for recurrence in stage III in colon tumors lacking microsatellite instability [61]. These studies, as well as other studies, focused mainly on the fact that overexpression of AURKA leads to chromosomal instability. In normal cells, expression of AURKA protein is predominantly confined to the nucleus and subject to spatio-temporal regulation during mitotic progression. In contrast, expression of AURKA protein is frequently observed in the cytoplasm, in addition to the nucleus, in cancer cells, suggesting an extended role of AURKA beyond regulation of mitosis [62]. This finding provides additional evidence supporting the wealth of signaling data for AURKA reported in upper GI cancers (summarized in the section above). For instance, Tseng and colleagues found that AURKA enhances formation and aggregation of mutant Ras (RasV12) through regulation of RAS/MEK/ERK pathways and AKT phosphorylation in colon cancer [63]. Aurora kinase pharmacological inhibition sensitized colon cancer cells to Tumor necrosis factor (TNF) and TNF-related apoptosis-inducing ligand (TRAIL) [64]. In addition, AURKA inhibition, using specific or pan Aurora kinase inhibitors, sensitized colon cancer cells to chemotherapy [65], TNF or TRAIL induced apoptosis [64] as well as mitotic failure and cell death when inhibited along with SRC [66]. Other reports showed that pharmacological inhibition of AURKA with MLN8054 in colon cancer HCT-116 xenografts induces senescence in vivo [36]. These findings suggest that more studies are needed to better characterize the role of AURKA in colon cancer signaling and therapeutics.

AURKA in pancreatic cancer
Overexpression of AURKA was reported in pancreatic cancer [26], in the early stages of abnormalities in pancreatic ducts and ductal dysplasia in transgenic mouse model for pancreatic cancer [67], and linked to chromosone instability and centrosome abnormality [68]. As observed in other GI cancers, suppression of AURKA using RNA interference [69] or small molecule inhibitor SNS-314 [70] suppresses tumor growth and enhances chemosensitivity. Similar results were obtained with specific AURKA inhibitor CYC3 in combination with Paclitaxel [71]. In addition, AURKA plays a role in protecting human pancreatic ductal adenocarcinoma cells from autophagic cell death induced by metabolic stress [72]. Interestingly, while it was shown in colorectal cancer that AURKA regulates MEK/ERK pathway [63], it was reported that AURKA is a downstream target of this pathway in pancreatic cancer [73], raising the possibility of an existing positive feedback loop between AURKA and MEK/ERK pathway. This signaling loop further underscores the potential therapeutic benefit of targeting AURKA in pancreatic cancer. Additionally, AURKA can phosphorylate RalA at Ser194 and regulate its subcellular localization, which is essential for Ras-
mediated cellular transformation [74]. However, further studies by the same group failed to show correlation of RalA (S194) phosphorylation with responsiveness to MLN8237, indicating that the principal target of AURKA may not be RalA [75].

**AURKA in liver cancer**

In human hepatocellular carcinoma (HCC), AURKA was found to be overexpressed at mRNA level in 61% of HCC samples [30], whereas gene amplification was recorded in only 3 out of 224 HCC samples [30]. Notably, high expression levels of AURKA were associated with high-grade, high-stage tumors and poor outcome. Microarray studies suggested that AURKA phosphorylates and stabilizes hepatoma up-regulated protein (HURP) [76], a cell cycle regulated gene that is overexpressed in human hepatocellular carcinoma (HCC) [77]. On the other hand, it was reported that hypoxia and hypoxia-inducible factor-1 (HIF-1) are important in the tumor microenvironment and could regulate AURKA at the transcriptional level [78,79]. Other studies showed that AURKA, can in turn, regulate HIF-1α through activation of AKT and p38-MAPK signaling pathways leading to malignant phenotypes of HCC [80], indicating a positive feedback loop sustaining continuous activation of AURKA. Several preclinical studies investigated the effects of AURKA inhibition in HCC. For example, a report showed that the pan Aurora inhibitor PHA-739358 inhibits HCC tumor growth in a tumor xenograft mouse model [81]. Further, AURKA inhibition with small molecule R1498 was found to target mitosis pathway and suppress angiogenesis [82]. These studies emphasize the multifaceted roles of AURKA in HCC and imply AURKA as a feasible druggable target in HCC.

**Clinical development of aurora kinase A inhibitors**

The aforementioned preclinical studies shed light on the roles and contributions of AURKA in tumorigenesis, which serve as premise for the development of several pan Aurora kinase inhibitors (AKIs) and selective inhibitors of AURKA. In the following section, we will focus on the present investigational AURKA inhibitors in completed, ongoing, or planned clinical trials.

**MLN8237 (alisertib)**

MLN8237 (alisertib) is a second generation derivative of the initial small molecule MLN8054, developed by Millennium Pharmaceuticals, Inc. Both generations work as highly specific ATP-competitive AURKA inhibitors with an IC50 of 2 nM in chronic myeloid leukemia (CML) for MLN8237 [83,84]. The MLN8237 IC50 values vary in other cancers, ranging from 6.7 nM in HeLa cells to 469 nM in DLD-1 colon cancer cell line [85]. MLN8237 can target AURKB at higher doses (396.5 nM) [35,85]. The first generation MLN8054 was terminated in phase 1 clinical trials due to off-target toxicities [86]. Both drugs are ATP competitive, where they bind and inhibit AURKA phosphorylation at T288. In murine xenograft models, MLN8237 was well tolerated with doses ranging from 15 to 40 mg/kg/d. MLN8237 was also found to be well absorbed and steady state plasma levels were reached within 7 days of twice daily dosing in phase 1 clinical trials [87]. Investigations of MLN8237 in preclinical studies have shown that it induces abnormal G2/M cell cycle arrest, abnormalities in mitotic spindles, and apoptosis in upper GI cancers [48,49,53]. In addition, MLN8237 down-regulates several oncogenic pathways such as NF-κB [49,88], AKT [19], and STAT3 [55] in cancer cells. On the other hand, several reports demonstrated that treatment with MLN8237 could activate p53 [47,48,89] and p73 [52,56] apoptotic pathways. The effects of MLN8237 were tested in several non-GI cancers. It has been shown that MLN8237 sensitized PC3 and DU145 prostate cancer cells to radiation, increased the DNA double-strand breaks, induced G2/M cell cycle arrest and polyploidy [90]. Treatment of OVCAR-5 and SKOV3ip2 ovarian cancer cells with MLN8237 resulted in inhibition of cytoskeletal regulatory SRC (assessed by decreased phosphorylation at Tyr-416) and decreased migration and adhesion [18]. Moreover, MLN8237 has been tested on many pediatric cancer cell lines like Ewing sarcoma, neuroblastoma, glioblastoma, rhabdomyosarcoma, ALL, and AML where it inhibited cell growth and delayed tumor growth [91]. In vitro and in vivo tumor xenografts mouse models showed that MLN8237 enhances anti-tumor activity of chemotherapeutics. For instance, dual treatment of MLN8237 with Docetaxel enhanced apoptosis and anti-tumor activity in lymphoma [92] and UGI adenocarcinomas cell models [53]. Similarly, a combination of Cisplatin with MLN8237 had robust anti-tumor activity in tumor xenograft models of esophageal adenocarcinomas [57]. In B-cell Non-Hodgkin Lymphoma, MLN8237 in combination with Vincristine and Rituximab showed robust cell death in vitro and had curative effects in vivo using mantle cell lymphoma (MCL) mouse xenograft model [93]. Collectively, the present data indicate that MLN8237 is an effective drug with high specificity and limited off target activity that works in various models. Notably, there are 49 clinical trials with MLN8237 in leukemia, breast, lung, colorectal, ovarian, and pancreatic cancers (clinicaltrials.gov; March 2015). Phase 1 clinical studies of the drug as a single agent demonstrate preliminary activity where 37% of patients achieved a best response of stable disease for more than 6 months in some solid tumors (colorectal cancer, chondrosarcoma, leiomyosarcoma, and liposarcoma) with modest toxicity such as nausea, stomatitis, and alopecia among other adverse effects [87]. The recommended
phase 2 dose of MLN8237 is 50 mg orally given twice daily on days 1–7 of a 21-day cycle for various solid tumors and hematologic malignancies [94]. Phase 2 studies of MLN8237 as a single agent are ongoing in multiple tumor types including lung, breast, ovarian, UGI, and pancreatic cancers (Table 2). In some of the clinical trials, MLN8237 has been tested in combination with other drugs such as Cetuximab and Docetaxel among others (Table 2). A recent phase 2 clinical trial of MLN8237 as a single agent in advanced solid tumors revealed that 9% of patients (4 out of 47 patients) with gastro-esophageal adenocarcinoma partially responded to the treatment [95]. A newly registered phase 1 clinical trial (NCT02319018) is ongoing to investigate the side effects of MLN8237 in combination with other chemotherapeutic drugs (fluorouracil, leucovorin calcium, oxaliplatin). This clinical trial will be the first to evaluate MLN8237 exclusively in gastrointestinal tumors (clinicaltrials.gov, Table 2).

ENMD-2076

ENMD-2076 was originally developed by EntreMed, Inc. as a selective AURKA inhibitor with an IC50 of 14 nM in biochemical assays [96]. However, ENMD-2076 was found to inhibit several other oncogenic kinases at different IC50 including FLT3 (1.86 nM), SRC (20.2 nM), VEGFR3 (15.9 nM), VEGFR2 (58.2 nM), PDGFRα (56.4 nM), and FGFR1 (92.7 nM) [96]. This drug was shown to induce G2/M cell cycle arrest and apoptosis, consistent with AURKA inhibition responses. ENMD-2076 was found to be selectively toxic to multiple myeloma (MM) cells but minimally toxic to hematopoietic progenitor cells [97]. Interestingly, exposure as short as 6 hours induces apoptosis and reduces AURKA auto-phosphorylation at T288; however, this was achieved at doses that also inhibited AURKB and several other kinases [97]. In vitro studies in multiple myeloma showed that treatment with ENMD-2076 inhibited AKT phosphorylation, and thus, altered the activity of some of its targets, including GSK3β, survivin, and XIAP [97]. Additionally, ENMD-2076 was shown to down-regulate phosphorylation of STAT3 at Ser-727 [97]. In mouse xenograft models of multiple myeloma, ENMD-2076 showed good tolerability at doses up to 200 mg/kg, and immunohistochemistry analysis revealed reduced Ki67 and increased cleaved caspase-3 expression levels [97]. In a patient-derived xenograft model of CRC, ENMD-2076 inhibited tumor growth, which led to regression; this was associated with significant reduction in 18-FDG uptake at day 3 and 21 of treatment [98]. In breast cancer, ENMD-2076 was most effective against triple-negative tumors with increased mutant p53 expression [99]. In addition, cells lacking estrogen receptor expression and/or HER2 overexpression were the most sensitive cells to the drug [99]. A completed phase 1 clinical trial indicated that this drug is tolerable at 160 mg/m² daily administered orally in patients with advanced solid tumors [100]. ENMD-2076 is currently being evaluated in phase 1 and 2 clinical trials, specifically in breast and ovarian cancers (clinicaltrials.gov, Table 2).

MK-5108

MK-5018 (VX689) is a specific AURKA inhibitor (IC50: 0.046 nM) developed by Vertex Pharmaceuticals [101]. MK-5018 also inhibits AURKB and AURKC, although at higher doses (200 folds higher than AURKA) with variable IC50 values among different cancer cell lines [101]. Tumor xenografts treated with MK-5018 showed significant tumor inhibition at doses of 15 or 30 mg/kg twice daily for 12 days, indicating the high tolerability of the drug [101]. In addition to a typical AURKA inhibition response (polyploidy and cell cycle arrest), inhibition of NF-kB activity and reduction of cytokine production were observed after treatment of ovarian cancer stem cells with MK-5108 [102]. Further, MK-5108 was investigated in combination with other therapeutic agents. For instance, MK-5108, in combination with histone deacetylase inhibitor, vorinostat, induced lymphoma cell death along with reduction of c-Myc, hTERT, and micro RNA levels in vitro [103]. In a colon cancer xenograft mouse model, MK-5108 was tested in combination with Docetaxel and showed additive anti-tumor activity as compared to animals that received Docetaxel alone [101]. A completed phase 1 clinical trial of MK-5108 as a single agent or in combination with Docetaxel to test its safety, side effects, and tolerability showed moderate toxicities with some clinical activity as a single agent in patients with advanced and/or refractory solid tumors [104] (clinicaltrials.gov, Table 2).

Conclusions

Since their discovery, aurora kinases have been under constant investigation to uncover their roles in carcinogenesis. Several studies have indicated that AURKA is overexpressed and/or amplified in different malignances relative to normal cells. A large body of literature has shown that overexpression of AURKA mediates several pro-tumorigenic functions in addition to mitosis; thereby suggesting AURKA as a potential therapeutic target. Several studies [19,48,49,52,55] identified multiple downstream targets of AURKA involved in critical cellular functions. These studies demonstrated that AURKA not only plays a role in regulating cell cycle and mitosis, but also interacts with a number of key oncogenic signaling networks, suggesting that AURKA is located at a signaling hub in cancer cells. Notably, many of these molecular regulations were established in GI cancers. These findings could be applicable to other types of
| Inhibitor  | Chemical structure | Target, selectivity (IC50) | NCT number, phase, status | Cancer type | Ref. |
|-----------|--------------------|-----------------------------|---------------------------|-------------|-----|
| MLN8237   | ![Chemical structure](image) AURKA (2 nM) | NCT01898078, Phase 1, Ongoing | Advanced Solid Tumors; Lymphoma | [95] |
|           |                    | NCT01045421, Phase 1/Phase 2, Completed | Nonhematological Malignancies | [95] |
|           |                    | NCT01091428 Phase 1/Phase 2, Ongoing (Agent in combination with Paclitaxel) | Ovarian Carcinoma; Fallopian Tube Cancer; Peritoneal Cancer; Breast Carcinoma | [95] |
|           |                    | NCT01471964, Phase 1/Phase 2, Ongoing (Agent in combination with Erlotinib) | Metastatic or Recurrent Non-Small Cell Lung Cancer | [95] |
|           |                    | NCT02114229, Phase 2, Ongoing | Malignant Rhabdoid Tumor; Atypical Teratoid Rhabdoid Tumor | [95] |
|           |                    | NCT00962091, Phase 1, Completed | Advanced Solid Tumors | [95] |
|           |                    | NCT01512758, Phase 1, Completed | Adult East Asian Patients With Advanced Solid Tumors or Lymphomas | [95] |
|           |                    | NCT02109328, Phase 2, Ongoing | Bladder Cancer; Transitional Cell Carcinoma | [95] |
|           |                    | NCT01812005, Phase 2, Ongoing (Agent in combination with Rituximab) | Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | [95] |
|           |                    | NCT0197825, Phase 1/Phase 2, Ongoing (Agent in combination with Rituximab and Vincristine) | Relapsed or Refractory Aggressive B-Cell Lymphoma | [95] |
|           |                    | NCT00500903, Phase 1, Completed | Advanced Solid Tumors | [95] |
|           |                    | NCT00697346, Phase 1, Completed | Advanced Hematological Malignancies | [95] |
|           |                    | NCT01799278, Phase 2, Ongoing | Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer | [95] |
|           |                    | NCT00807495, Phase 2, Completed | Aggressive Non-Hodgkin’s Lymphoma | [95] |
|           |                    | NCT01567709, Phase 1, Ongoing (Agent in combination with Vorinostat) | Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | [95] |
|           |                    | NCT00651664, Phase 1, Completed | Advanced Solid Tumors; Lymphomas | [95] |
|           |                    | NCT01695941, Phase 1, Ongoing (Agent in combination with Bortezomib and Rituximab) | Relapsed or Refractory Mantle Cell Lymphoma or B-Cell Low Grade Non-Hodgkin Lymphoma | [95] |
|           |                    | NCT01154816, Phase 2, Completed | Recurrent or Refractory Solid Tumors or Leukemia | [95] |
|           |                    | NCT02038647, Phase 2, Ongoing (Agent in combination with Placebo and Paclitaxel) | Small Cell Lung Cancer | [95] |
|           |                    | NCT01779843, Phase 1, Ongoing (Agent in combination with Cytarabine and Idarubicin) | Acute Myeloid Leukemia | [95] |
|           |                    | NCT0835018, Phase 2, Completed | Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome | [95] |
|           |                    | NCT016777559, Phase 1, Ongoing (Agent in combination with Nab-Paclitaxel) | Advanced Solid Malignancies | [95] |
|           |                    | NCT01924260, Phase 1, Ongoing (Agent in combination with Gemcitabine) | Solid Tumors or Pancreatic Cancer | [95] |
Table 2 Selected clinical trials of Aurora kinases inhibitors (Continued)

| NCT          | Phase     | Status       | Agent Description                                                                 | Disease Estado                  |
|--------------|-----------|--------------|-----------------------------------------------------------------------------------|---------------------------------|
| 01897012     | Phase 1   | Ongoing      | (Agent in combination with Romidepsin)                                              | Relapsed or Refractory B-Cell or T-Cell Lymphomas |
| 0134553      | Phase 1/Phase 2 | Ongoing (Agent in combination with Bortezomib) | Relapsed or Refractory Multiple Myeloma                                             |
| 1482962      | Phase 3   | Ongoing      | (Agent in combination with Pralatrexate, Gemcitabine and Romidepsin)                | Relapsed/Refractory Peripheral T-Cell Lymphoma |
| 01848067     | Phase 1/Phase 2 | Ongoing (Agent in combination with Abiraterone acetate and Prednisone) | Hormone-Resistant Prostate Cancer                                                 |
| 01466881     | Phase 2   | Ongoing      | Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma                      |
| 0123337      | Phase 1   | Ongoing      | (Agent in combination with Irinotecan hydrochloride)                               | Advanced Solid Tumors or colorectal Cancer  |
| 01714947     | Phase 1   | Completed    |                                                                                  | Advanced Solid Tumors; Lymphoma    |
| 01094288     | Phase 1   | Ongoing      | (Agent in combination with Docetaxel)                                              | Advanced Solid Tumors Including Castration-Resistant Prostate Cancer             |
| 01639911     | Phase 1   | Ongoing      | (Agent in combination with Pazopanib)                                              | Solid Tumors                     |
| 00853307     | Phase 2   | Completed    |                                                                                  | Ovarian, Fallopian Tube, or Peritoneal Carcinoma                                |
| 01486882     | Phase 1   | Completed    | (Agent in combination with Cetuximab and radiotherapy)                             | Head and Neck Cancer              |
| 01316692     | Phase 2   | Ongoing      |                                                                                  | Unresectable Stage III-IV Melanoma                                              |
| 0187991      | Phase 2   | Ongoing      | (Agent in combination with Paclitaxel)                                             | Metastatic or locally recurrent breast cancer                                    |
| 02259010     | Phase 1   | Ongoing      | (Agent in combination with Itraconazole)                                           | Advanced Solid Tumors or Relapsed/Refractory Lymphoma                            |
| 02367352     | Phase 1   | Ongoing      | (Agent in combination with Paclitaxel)                                             | East Asian Patients With Advanced Solid Tumors                                  |
| 02319018     | Phase 1   | Ongoing      | (Agent in combination with Leucovorin Calcium, Fluorouracil, and Oxaliplatin)      | Gastrointestinal Tumors                                                        |
| 0219789      | Phase 1   | Ongoing      | (Agent in combination with Fulvestrant)                                            | Hormone Receptor Positive, Metastatic or Advanced Breast Cancer                  |
| 02186509     | Phase 1   | Ongoing      | (Agent with radiation)                                                            | Recurrent High-Grade Gliomas                                                  |
| 01848067     | Phase 1&2 | Ongoing      | (Agent with Abiraterone acetate and Prednisone)                                    | Hormone-Resistant Prostate Cancer                                              |
| 01779843     | Phase 1   | Ongoing      | (Agent with Cytarabine and Idarubicin)                                             | Acute Myeloid Leukemia                                                         |
tumors. However, rigorous investigations are required before a conclusion can be drawn. AURKA activates multiple oncogenic signaling pathways while suppressing critical tumor suppressor functions of p53 [48,89] and p73 [52,56] in cancer cells. AURKA regulates several fundamental properties of carcinogenesis such as cell survival, growth, invasion, inflammation, and angiogenesis. Furthermore, AURKA was shown to regulate pluripotency of embryonic stem cells [13,14], which may suggest that AURKA plays a role in regulating stemness features of cancer cells.

Although our understanding of the role of aurora kinases has improved significantly over the past few years, and several pan or specific Aurora inhibitors were developed with variable specificities, only a few have moved forward in clinical trials. One of the most widely studied inhibitors is MLN8237 (alisertib), which has been investigated in preclinical studies using in vitro and tumor xenograft mouse models with promising anti-tumor effects, alone and in combination with Cisplatin [57] or Docetaxel [53]. MLN8237 as single agent or in combination with chemotherapeutics has been evaluated in clinical trials (Table 2). In spite of the extensive preclinical studies on AURKA, few clinical trials were undertaken to evaluate the potentiality of AURKA as a target in GI cancers. The most advanced clinical trial (phase 3) is testing MLN8237 in hematologic malignancies (clinical trial# NCT01482962). In solid tumors, phase 2 clinical trials are currently testing MLN8237 alone or in combination with other chemotherapeutics or biologics (Paclitaxel, Erlotinib, Rituximab, Vincristine among others, Table 2). ENMD-2076 is another specific AURKA inhibitor, currently in phase 2 for ovarian and breast cancers (NCT01914510, NCT01639248, NCT01104675) that has not been tested in GI cancers. Given the experience from other targeted therapy approaches, it is unlikely that AURKA inhibition alone would be sufficient to achieve the desired therapeutic response in solid tumors. Clinical trials utilizing combinations with other anti-cancer drugs may have higher probabilities of success in cancer cell killing by circumventing the expected resistance due to tumor heterogeneity. However, these approaches should be carefully developed as they could be hindered by increased toxicities.

It is also a critical priority to investigate and identify molecular biomarkers of response and resistance to AURKA inhibitors. Biomarker based strategies for patient enrollment into clinical trials hold the future

---

**Table 2 Selected clinical trials of Aurora kinases inhibitors (Continued)**

| Trial ID | Phase | Status | Disease Category |
|----------|-------|--------|-----------------|
| NCT02327169 | Phase 1 | Ongoing | Agent with MLN2480, MLN0128, and Paclitaxel |
| NCT00543387 | Phase 1 | Completed | (Agent in combination with Docetaxel) |
| NCT01914510 | Phase 2 | Ongoing | Ovarian Clear Cell Cancers |
| NCT01719744 | Phase 2 | Ongoing | Advanced/Metastatic Soft Tissue Sarcoma |
| NCT00904787 | Phase 1 | Completed | Relapsed or Refractory Hematological Malignancies |
| NCT01639248 | Phase 2 | Ongoing | Advanced and Metastatic Triple-Negative Breast Cancer |
| NCT00806065 | Phase 1 | Completed | Multiple Myeloma |
| NCT00658671 | Phase 1 | Completed | Advanced Cancer |
| NCT0234986 | Phase 2 | Ongoing | Advanced Fibrolamellar Carcinoma |
| NCT01104675 | Phase 2 | Completed | Ovarian Cancer |
direction for personalized cancer therapy. Based on the available literature, several molecules could be potential biomarkers of response or resistance to AURKA inhibition. These molecules include targets of AURKA such as P53, P73, AKT, BRCA 1&2, STAT3, NF-κB, MDM2, SRC, and MYC [16,17,48,49,52,55,56]. For instance, a study aimed to predict biomarkers of response to the aurora kinase inhibitor, PF-03814735, found that the status of the MYC gene family and retinoblastoma pathway members significantly correlated with the efficacy of the inhibitor in small cell lung cancer and colon cancer cell lines [105]. Identification of biomarkers that can reliably predict benefits from AURKA inhibitors should be developed as an integral part of clinical trials in our pursuit for personalized medicine.

In summary, while there is relatively strong biology and several preclinical studies supporting AURKA as an attractive therapeutic target in GI cancers along with the availability of multiple inhibitors, larger and carefully designed clinical trials will be needed to clearly establish the role of AURKA inhibitors in the treatment of GI cancers.

Abbreviations
GI: Gastrointestinal; AURKA: Aurora kinase A; AURKB: Aurora kinase B; AURKC: Aurora kinase C; TPX2: Targeting protein for Xklp2; BRCA1/2: Breast cancer susceptibility gene; VEGF: Vascular endothelial growth factor; UG: Upper gastrointestinal; ESCC: Esophageal squamous cell carcinoma; EAC: Esophageal adenocarcinomas; CCND1: Cyclin D1; FGF: Fibroblast growth factor; STAT3: Signal transducer and activator of transcription 3; BCL-xL: B-cell lymphoma-extra large; Bcl2: B-cell lymphoma 2; MCL1: Myeloid cell leukemia; HCC: Human hepatocellular carcinoma; HIF-1: Hypoxia-inducible factor-1; CML: Chronic myeloid leukemia; ALL: Acute lymphoblastic leukemia; CRC: Colorectal cancer; CHFR: Checkpoint with modulation of apoptosis; UGI: Upper gastrointestinal; ESCC: Esophageal squamous cell carcinoma; EAC: Esophageal adenocarcinomas; CCND1: Cyclin D1; FGF: Fibroblast growth factor; STAT3: Signal transducer and activator of transcription 3; BCL-xL: B-cell lymphoma-extra large; Bcl2: B-cell lymphoma 2; MCL1: Myeloid Cell Leukemia; HDM2: Human double minute 2; PUMA: p53 upregulated modulator of apoptosis; CRC: Colorectal cancer; CHFR: Checkpoint protein with forkhead and ring finger domains; MAPK: Mitogen-activated protein kinases; ERK: Extracellular signal-regulated kinases; HURP: Hepatoma up-regulated protein; HCC: Human hepatocellular carcinoma; HIP-1: Hypoxia-inducible factor-1; CML: Chronic myeloid leukemia; ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; MCL1: Mantle cell lymphoma; FLT3: FMS-like tyrosine kinase 3; PDGFRA: Alpha-type platelet-derived growth factor receptor; MM: Multiple myeloma; FDG: Fluorodeoxyglucose; HER2: Human epidermal growth factor receptor; H1ERT2: Human telomerase reverse transcriptase.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
AK: Prepared the scientific material, write the main text, and made figures; AB: revised the scientific contents and edited the text; LG: revised the scientific contents; WE: developed the structure of the review, revised the scientific material, and edited the contents. All authors read and approved the final manuscript.

Acknowledgements
This review was supported by R01CA131225 from the National Institutes of Health. The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute or Vanderbilt University.

Author details
1Department of Surgery, Vanderbilt University Medical Center, 760 PRB, 2220 Pierce Avenue, 37232-6308 Nashville, TN, USA. 2Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA. 3Department of Hematology, Department of Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. 4Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN, USA.

Received: 14 November 2014 Accepted: 28 April 2015
Published online: 20 May 2015

References
1. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001;2:21–32.
2. Brown JR, Koretke KK, Birkenland ML, Sanseau P, Patrick DR. Evolutionary relationships of Aurora kinases: Implications for model organism studies and the development of anti-cancer drugs. BMC Evol Biol. 2004;4:39-49.
3. Kollareddy M, Dzubak P, Zheleva D, Hadjuch M. Aurora Kinases: Structure, Functions and Their Association with Cancer. Biomed Pac Olomouc. 2008;152:27–33.
4. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003;4:842–54.
5. Sen S, Zhou HY, White RA. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene. 1997;14:2195–200.
6. Tanner MM, Grenman S, Koul A, Johansson O, Melzer P, Pejovic T, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res. 2000;6:1833–9.
7. Hannak E, Kirkham M, Hyman AA, Oegema K. Aurora-A kinase is required for centrosome maturation in Caenorhabditis elegans. J Cell Biol. 2001;155:1109–15.
8. Hirot a T, Kunitoku N, Sasayama T, Zhang DW, Nitta M, et al. Aurora-A and an interacting activator, the UIM protein Ajuba, are required for mitotic commitment in human cells. Cell. 2003;14:585–98.
9. Yoon Y, Cowley DO, Gallant J, Jones SN, Van Dyke T, Rivera-Perez JA. Conditional Aurora A deficiency differentially affects early mouse embryo patterning. Dev Biol. 2012;371:77–85.
10. Cowley DO, Rivera-Perez JA, Schlekelman M, He YJ, Oliver TG, Lu L, et al. Aurora-A Kinase Is Essential for Bipolar Spindle Formation and Early Development. Mol Cell Biol. 2009;29:1059–71.
11. Lu L, Wood JL, Ye L, Minter-Dykhouse K, Saunders TL, Yu XC, et al. Aurora A Is Essential for Early Embryonic Development and Tumor Suppression. J Biol Chem. 2009;283:1785–90.
12. Tsai MY, Wiese C, Cao K, Martin O, Donovan P, Ruderman J, et al. A Ran signalling pathway mediated by the mitotic kinase Aurora A in spindle assembly. Nat Cell Biol. 2003;5:242–8.
13. Li Z, Rana TM. A kinase inhibitor screen identifies small-molecule enhancers of reprogramming and iPSC cell generation. Nat Commun. 2012;3:1085.
14. Lee DF, Su J, Ang YS, Carvajal-Vergara X, Mulerio-Navano S, Pereira CF, et al. Regulation of Embryonic and Induced Pluripotency by Aurora Kinase-p53 Signaling. Cell Stem Cell. 2012;11:179–94.
15. Sourisseau T, Maniotis D, McCarthy A, Tang C, Lord CJ, Ashworth A, et al. Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. EMBO Mol Med. 2010;2:130–42.
16. Sankaran S, Crane DE, Palazzo RE, Parvin JD. Aurora-A kinase regulates breast cancer associated gene 1 inhibition of centrosome-dependent microtubule nucleation. Cancer Res. 2007;67:11186–94.
17. Yang G, Chang B, Yang F, Guo XQ, Cai RQ, Xiao X, et al. Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2. Clin Cancer Res. 2010;16:3171–81.
18. Do TV, Xiao F, Bickel LE, Klein-Szanto AJ, Pathak HB, Hua X, et al. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene. 2013;32:539-549.
19. Dar AA, Belhiri A, El-Rifai W. The aurora kinase A regulates GSK-3beta in gastric cancer cells. Oncogene. 2009;28:8866–75.
20. Eyers PA, Erikson E, Chen LG, Maller JL. A novel mechanism for activation of the protein kinase aurora A. Curr Biol. 2003;13:691–7.
21. Ochi T, Fujiwara H, Suemori K, Azuma T, Yakushijin Y, Hato T, et al. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood. 2009;113:66–74.
22. Park HS, Park WS, Bondaruk J, Tanaka N, Katayama H, Lee S, Spiess PE, Steinberg JR, Wang Z, Katz RL, et al. Quantitation of aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst. 2008;100:1401-1411.
23. Tanaka T, Kimura M, Matsuoka K, Fukuda D, Mori H, Okano Y. Centrosomal kinase AK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res. 1999;59:2041–4.
24. Watanabe T, Imoto I, Katahira T, Hirasaawa A, Ishiwata I, Emi M, et al. Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers. Jpn J Cancer Res. 2002;93:1114–22.

25. Bischoff JR, Anderson L, Zhu YF, Mossie K, Ng L, Souza B, et al. A homologue of Dro sophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998;17:3552–65.

26. Li DT, Zhu J, Fierzi PF, Abbruzzese JL, Evans DB, Cleary K, et al. Overexpression of oncogenic STK15/BTAK/aurora A kinase in human pancreatic cancer. Clin Cancer Res. 2003;9:991–7.

27. Kamada K, Yamada Y, Hirota T, Fujimoto H, Takahama Y, Ueno M, et al. Amplification/overexpression of Aurora-A in human gastric carcinoma. Potential role in differentiated type gastric carcinogenesis. Oncol Rep. 2004;12:2593–9.

28. Yang SB, Zhou XB, Zhu HX, Quan LP, Bai JF, He J, et al. Amplification and overexpression of Aurora-A in esophageal squamous cell carcinoma. Oncol Rep. 2007;17:1083–8.

29. Rojanala S, Han HY, Munoz RM, Browne W, Nagle R, Von Hoff DD, et al. The mtorc serine therine kinase, Aurora-A, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther. 2004;3:451–7.

30. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hematopoietic cell carcinoma. Clin Cancer Res. 2004;10:2065–71.

31. Cammariere P, Scoppettì A, Todaro M, Eterno V, Francescangeli F, Moyer MP, et al. Aurora-A is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res. 2010;70:4655–62.

32. Lee HH, Zhu YS, Govindasamy KM, Copalan G. Downregulation of Aurora-A overrides estrogen-mediated growth and chemoresistance in breast cancer cells. Endocr Relat Cancer. 2008;15:765–75.

33. Wang X, Zhou YX, Qiao W, Tominaga Y, Ouchi M, Ouchi T, et al. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene. 2006;25:1148–58.

34. Zhou H, Kuang J, Zhong L, Luo WL, Gray JW, Sahin A, et al. Tumour amplification kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet. 1998;20:189–93.

35. Gorgun G, Calabrese E, Hideshima T, Ecdedy J, Perrone G, Mani M, et al. A novel Aurora-A kinase inhibitor MLN2379 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010;115:2022–13.

36. Huck JJ, Zhu YS, Govindasamy KM, Copalan G. Downregulation of Aurora-A 583; potentiates apoptosis in tumor cells. Mol Cancer Ther. 2007;6:1093–44.

37. Katsha A, Aras I, Soutto M, Belkhiri A, El-Rifai W. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res. 2008;68:8998–9004.

38. Sehdev V, Katsha A, Ecdedy J, Ziaia A, El-Rifai W. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas. Cancer. 2013;119:904–14.

39. Guan Z, Wang X, Zhu XF, Huang XF, Xu J, Wang LH, et al. Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res. 2007;67:1046–44.

40. Katsha A, Aras I, Soutto M, Belkhiri A, El-Rifai W. AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers. Mol Oncol. 2014. doi:10.1016/j.molonc.2014.05.012.

41. Katayama H, Wang J, Treekikkammongkol W, Kawai H, Sasai K, Zhang H, et al. Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell. 2012;21:119–211.

42. Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, Ecdedy J, et al. The aurora kinase A inhibitor MLN2379 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther. 2012;11:763–74.

43. Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F, et al. Identification of TKIs/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet. 2003;34:403–12.

44. Hiekenen T, Salovaara R, Medcîn JP, Janhvinen H, Karhu A, Aaltonen LA. Preferential amplification of AURKA 91A (ile31) in familial colorectal cancers. Int J Cancer. 2006;118:505–8.

45. Fu Z, Regan K, Zhang LZ, Maders MB, Thibeodeau SN, French A, et al. Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice. J Cell Sci. 2009;122:2174–84.

46. Belt EJ, Brosens RP, Delis-van Diemen PM, Bril H, Tissien M, van Essen DF, et al. Cell cycle proteins predict recurrence in stage II and III colon cancer. Ann Surg Oncol. 2012;19:Suppl 3:S3682–92.

47. Burum-Auenes E, De Angelis PM, Schjølberg AR, Kravik K, Aune M, Clausen OP. Subcellular localization of the spindle proteins Aurora A, Mad2, and BubR1 assessed by immunohistochemistry. J Histochem Cytochem. 2007;55:4777–86.

48. Tseng YS, Lee JC, Huang CYF, Liu HS. Aurora-A overexpression enhances cell-aggregation of Ha-ras transfectants through the MEK/ERK signaling pathway. BMC Cancer. 2009;9:435–466.

49. Kuratkin A, Senapati VE, Verma R, Mellone BG, Vella AT, Giudicane C. Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest. Biochem Pharmacol. 2012;83:1217–27.

50. Shimone Y, Lin WH, Shiao HY, Hsieh PH, Hsu JT, Ouchi T. A novel aurora-A inhibitor, BPR1KO06951, sensitizes colorectal tumor cells to 5-fluorouracil (5FU)-treatment. Cell death in esophageal adenocarcinomas correlates with potent antiapoptotic functions. Cancer. 2008;112:1688–98.

51. Dar AA, Ziaia A, Pizuelo MB, Correa P, Koyama T, Belkhiri A, et al. Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer. 2000;88:11268–98.

52. Ratushny V, Pathak HB, Beherany N, Tilmannova Y, Xiao F, Li T, et al. Dual inhibition of SRC and Aurora kinases induces postmitotic attachment arrest in multiple myeloma. Blood. 2010;115:5202–12.

53. Sehdev V, Katsha A, Ecdedy J, Ziaia A, El-Rifai W. Overexpression of oncogenic STK15/BTAK/aurora A kinase in human gastric carcinoma. Mol Oncol. 2006;25:699–703.

54. Katsha A, Soutto M, Belkhiri A, El-Rifai W. AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers. Mol Oncol. 2014. doi:10.1016/j.molonc.2014.05.012.

55. Katayama H, Wang J, Treekikkammongkol W, Kawai H, Sasai K, Zhang H, et al. Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell. 2012;21:119–211.
69. Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohnura N, et al. RNA interference targeting aurora kinase suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 2005;65:2899–905.

70. Arbitrario JP, Belmont BJ, Eivanhik MJ, Flanagan WM, Fucini RV, Hansen SK, et al. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and closing flexibility in vivo. Cancer Chemother Pharmacol. 2010;65:707–17.

71. Lin Y, Richard M, Krippendorff BF, Bramhall JL, Harrington JA, Bairejo TY, et al. Paclitaxel and CAYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells. Br J Cancer. 2012;107:1692–701.

72. Hamid T, Cano CE, Grasso D, Garcia MN, Sandi ML, Calvo EL, et al. Nuprl1-aurora kinase A pathway provides protection against metabolic stress-mediated autophagic-associated cell death. Clin Cancer Res. 2012;18:5234–46.

73. Furukawa T, Kani N, Shiwaku HO, Soga N, Uehara A, Horii A. ALKRA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene. 2006;25:4834–9.

74. Lim KH, Brady DC, Kashatus DF, Ancile BB, Der CJ, Cox AD, et al. Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RaLa. Mol Cell Biol. 2010;30:508–23.

75. Neel NF, Stratford JK, Shinde V, Ecsedy JA, Martin TD, Der CJ, et al. Response to MLN8237 in Pancreatic Cancer Is Not Dependent on RaLa Phosphorylation. Mol Cancer Ther. 2014;13:122–33.

76. Yu CT, Hsu JM, Lee YG, Tsou AP, Chou CK, Huang CY. Phosphorylation and stabilization of HURP by aurora-A: Implication of HURP as a transforming target of aurora-A. Mol Cell Biol. 2005;25:779–800.

77. Tsou AP, Yang CW, Huang CYF, Yu RCT, Lee YG, Chang CW, et al. Identification of a novel cell cycle regulated gene, HURP, overexpressed in human hepatocellular carcinoma. Oncogene. 2003;22:3298–307.

78. Klein A, Flugel D, Rietmann T. Transcriptional regulation of serine/threonine kinase-15 (STK15) expression by hypoxy and Hif-1. Mol Cell Biol. 2008;19:3667–75.

79. Gao P, Wang R, Shen JJ, Lin F, Wang X, Dong K, et al. Hypoxia-inducible enhancer/alpha-fetoprotein promoter-driven RNA interference targeting STK15 suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. Cancer Sci. 2008;99:2209–17.

80. Cui SY, Huang JY, Chen YT, Song HZ, Huang GC, De W, et al. The role of Aurora A in hypoxia-inducible factor 1alpha-promoting malignant phenotypes of hepatocellular carcinoma. Cell Cycle. 2013;12:2849–66.

81. Benten D, Kellner G, Quaas A, Schrader J, Goebell H. Aurora A Inhibitor MLN8237 is Active in Resistant Pancreatic Cancer Cells but not Bone Marrow Precursor Cells. Mol Cancer Res. 2010;8:2122–30.

82. Zhang C, Wu XH, Zhang MF, Zhu LC, Zhao R, Xu DQ, et al. Small Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays, Clin Cancer Res. 2011;17:7614–24.

83. Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, Hajduch B, et al. Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in advanced solid tumors. Cancer Res. 2012;72:1567–74.

84. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, et al. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib. J Cell Mol Med. 2011;15:2057–70.

85. Manfredi MG, Ecsedy JA, Meeteza KA, Balani SK, Burenkova O, Chen W, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A. 2007;104:4106–11.

86. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, et al. Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays, Clin Cancer Res. 2011;17:7614–24.

87. Kollerreddy M, Zhuleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, Hajduch B, et al. Aurora A inhibitors: progress toward the clinic. Invest New Drugs. 2012;30:4211–32.

88. Cervantes A, Elez E, Roda D, Ecsedy J, Macanulla T, Venkatarkrishnan K, et al. Phase I pharmacokinetic/pharmacodynamic study of MLN237, an investigational, oral, selective aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012;18:760–74.

89. Brassouli P, Chan F, Savage K, Reis-Filho JS, Linardopoulos S. Aurora-A: regulation of nuclear-factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res. 2007;67:1689–95.

90. Yang H, He L, Kruk P, Nicola SV, Cheng JQ. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer. 2006;119:2034–12.

91. Moretti L, Niermann K, Schleicher S, Giacalone NJ, Varki V, Kim KW, et al. MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation. Int J Radiat Oncol Biol Phys. 2011;80:1189–97.

92. Maris JM, Morton CL, Golicik R, Kolb EA, Lock R, Carol H, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP), Pediatric Blood Cancer. 2010;55:26–34.

93. QW, Cooke LS, Liu X, Rimza L, Roe DJ, Manzolli A, et al. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol. 2011;81:881–90.

94. Mahadevan D, Stejskal A, Cooke LS, Manzolli A, Morales C, Pensky OD, et al. Aurora A Inhibitor (MLN237) plus Vincristine plus Rituximab in Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma. Clin Cancer Res. 2012;18:2210–9.

95. Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatarkrishnan K, et al. Phase I study of aurora kinase A inhibitor MLN8237 in advanced solid tumor: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res. 2012;18:4775–84.

96. Manfredi MG, Ecsedy JA, Bennouna J, Dees EC, Kayaleh O, et al. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol. 2015;16:395–405.

97. Yang H, He L, Kruk P, Nicola SV, Cheng JQ. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer. 2006;119:2034–12.
109. Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, Ongusaha PP, et al. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem. 2004;279:19643–8.

110. Kelly KR, Shea TC, Goy A, Berdeja JG, Reeder CB, McDonagh KT, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2014;32:489–99.